ublituximab (Pending FDA Approval)

Brand and Other Names:
  • Print

Dosing & Uses

Chronic Lymphocytic Leukemia

Pending FDA approval for using in combination with Ukoniq (umbralisib) as a treatment for patients with chronic lymphocytic leukemia and small lymphocytic lymphoma



Mechanism of Action

CD20-directed cytolytic antibody; upon binding to CD20, ublituximab mediates B-cell lysis through 1) engagement of immune effector cells, 2) by directly activating intracellular death signaling pathways and/or, 3) activation of the complement cascade

CD20 antigen is expressed on the surface of pre B- and mature B-lymphocytes; the immune effector cell mechanisms include antibody-dependent cellular cytotoxicity and antibody-dependent cellular phagocytosis

Ublituximab has a specific glycosylation profile, with a low fucose content, that may enhance its ADCC response against malignant B cells



No images available for this drug.

Patient Handout

A Patient Handout is not currently available for this monograph.
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.